Background: Randomised controlled trials (RCTs) of adjunctive vitamin D in pulmonary
INTRODUCTION
The World Health Organisation estimates that 10.0 million people developed active tuberculosis in 2017, and that 1.6 million people died of this disease. 1 Existing antimicrobial treatment for active tuberculosis requires lengthy administration of a high pill burden that carries a significant risk of toxicity and has limited efficacy in drug-resistant disease. Adjunctive host-directed therapies (i.e. immunomodulatory therapies given in addition to antimicrobial treatment) have the potential to reduce duration of transmissibility, shorten antimicrobial therapy and improve outcomes in drug-resistant disease. 2 Vitamin D has attracted interest as a potential candidate on the basis of its historical use in tuberculosis treatment, 3 reported associations between vitamin D deficiency and susceptibility to tuberculosis infection and disease, 4, 5 and its recognized role in supporting antimycobacterial immune responses. 6, 7 Double-blind randomized placebo-controlled trials evaluating effects of vitamin D supplementation on sputum culture and/or smear conversion in patients receiving antimicrobial therapy for pulmonary tuberculosis have yielded conflicting results: four report favorable effects on their primary outcome in the study population as a whole, [8] [9] [10] [11] two report benefits on their primary outcome in sub-groups only, 12, 13 and four report no effects of the intervention on their primary outcome. [14] [15] [16] [17] Systematic reviews and aggregate data meta-analyses including at least some of these studies [18] [19] [20] [21] are all limited by lack of access to individual participant data, which precludes conduct of sub-group analyses to explore whether individual-level factors may modify responses to vitamin D supplementation. This is an important omission, because uneven distribution of such effect-modifiers between participants in different settings might underlie variation in results seen between trials.
For example, effects of vitamin D supplementation may be modified by drugsusceptibility of a patient's Mycobacterium tuberculosis isolate: this might be expected on the grounds that individuals with drug-resistant disease may stand to derive particular benefit from host-directed therapy where antimicrobial therapies are less effective. 2 Alternatively, effects of vitamin D supplementation may be stronger in, or restricted to, individuals with lower baseline vitamin D status, since these individuals might be expected to derive the greatest benefit from vitamin D replacement. This phenomenon has been demonstrated in other respiratory diseases. [22] [23] [24] We therefore set out to obtain individual participant data from the ten clinical trials listed above and meta-analyze them in order to obtain an updated estimate of overall efficacy, and to determine whether effects of this intervention vary according to the presence or absence of potential effect-modifiers.
METHODS

Protocol and Registration
The methods for this systematic review and meta-analysis were described in an outline protocol that was registered with the PROSPERO International Prospective Register of Systematic Reviews, number CRD42015020288
(http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42015020288 ).
Research ethics committee approval to contribute individual participant data from completed primary trials to the current meta-analysis was not required for any study.
Findings are reported according to the PRISMA guidelines for individual participant data meta-analysis. 25 
Selection of studies and participants
Double-blind, placebo-controlled randomized controlled trials of adjunctive vitamin D supplementation including patients receiving standard antimicrobial treatment for pulmonary tuberculosis were eligible for inclusion if the primary trial had been approved by a Research Ethics Committee, and if data on sputum culture and/or smear conversion were reported. Studies in which vitamin D was given in combination with another intervention were excluded if effects of vitamin D could not be isolated (e.g. by use of a factorial design). Studies in which a factorial design was used to investigate effects of other therapies alongside vitamin D were included, as these allowed effects of vitamin D to be isolated.
Individual participants in eligible studies were excluded if pulmonary tuberculosis was not confirmed by sputum culture or smear, i.e. we only included data from individual patients in the meta-analysis if they had either a positive sputum smear at baseline or a positive sputum culture at baseline or both.
Data Sources and Searches
Two investigators (DAJ and ARM) searched PubMed, EMBASE, the Cochrane Central
Register of Controlled Trials (CENTRAL) and Web of Science using the electronic search strategies described in the Appendix. Searches were regularly updated up to and including 10 th November 2017. No language restrictions were imposed. Two investigators (DAJ and ARM) determined which studies met the eligibility criteria.
Data Extraction and Quality Assurance
Individual participant data were requested from the Principal Investigator for each eligible trial, and the terms of collaboration were specified in a data transfer agreement, signed by representatives of the data provider and the recipient (Queen Mary University of London). Data were de-identified at source prior to transfer via email. On receipt, two investigators (DAJ and ARM) assessed data integrity by performing internal consistency checks and by cross-checking proportions of participants with positive 8-week sputum culture and smear by arm against those reported in published papers. Study authors were contacted to provide missing data and to resolve queries arising from these integrity checks. Once queries had been resolved, clean data were uploaded to the main study database, which was held in STATA IC v12 (College Station, TX, USA).
The following data relating to study characteristics were collected: study setting, 
Risk of Bias Assessment for Individual Studies
We used the Cochrane Collaboration Risk of Bias tool 26 to assess the following variables: sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, completeness of outcome data, evidence of selective outcome reporting and other potential threats to validity. Selectivity of reporting was assessed either by comparing study protocols against study reports, or by specifically asking study authors whether all pre-specified outcomes were reported.
Study quality was assessed independently by two investigators (ARM and DAJ), except for the trials in which ARM was an investigator, 12, 13 which were assessed by RR and MAH. Discrepancies were resolved by consensus.
Definition of Outcomes
The primary outcome of the meta-analysis was time from initiation of antimicrobial therapy to stable sputum culture conversion, estimated as the midpoint between the last positive sputum culture and the first negative sputum culture thereafter. This outcome was selected as primary because it is a recognized surrogate for treatment failure and relapse that reflects the longitudinal profile of culture results over time, as opposed to a single time point. 27 Participants who were unable to expectorate spontaneously at follow-up time points were deemed to be culture negative. Where participants were culture positive at 8-week follow-up (or earlier if lost to follow-up before this time point), time to sputum culture conversion was attributed as the number of days from the date of treatment initiation to the date of the last follow-up visit, and the censor variable was assigned a zero value to indicate that the endpoint of sputum culture conversion was not achieved. Secondary outcomes were time to stable sputum smear conversion, estimated as the midpoint between the last positive sputum smear and the first negative sputum smear thereafter; proportions of participants with negative sputum culture / smear after 8 weeks of antimicrobial therapy; weight after 8 weeks of antimicrobial therapy; and risk of death, study withdrawals, and potential adverse reactions to vitamin D supplementation (hypercalcemia or renal stones). Time to sputum culture / smear conversion was estimated only for trials where sputum was collected at intervals of two weeks or less, due to the potential for imprecision of such an estimate with less frequent sputum collection.
Data Synthesis and Analysis
DAJ and ARM analyzed the data using STATA IC, version 12. Our individual participant data meta-analysis approach followed published guidelines. 28 We did both one-step and two-step individual participant data meta-analyses for the primary outcome of time to sputum culture conversion. For secondary outcomes, we did one-step individual participant data meta-analysis only. In the one-step approach, individual participant data from all studies were modelled simultaneously while accounting for the clustering of participants within studies. We used mixed models, with a random effect for study and fixed effects for age and sex (reflecting an assumption that the influence of age and sex on response to treatment would not vary across trials) to obtain the pooled intervention effect with a 95% CI. We did not adjust for other covariates because missing values for some participants would have led to their exclusion from statistical analyses. We analyzed survival data using mixed-effects parametric survival models; effects of the intervention on time to sputum culture/smear conversion were expressed as adjusted hazard ratios (aHRs). Survival data for time to sputum culture and smear conversion were truncated at 8 weeks in order to capture effects of adjunctive vitamin D on the standardized background of intensive-phase antimicrobial therapy. We analyzed proportions of participants experiencing an event using mixed-effects logistic regression; effects of the intervention on dichotomous outcomes were expressed as adjusted odds ratios (aORs). In the two-step approach, individual participant data were first analyzed for each separate study independently to produce a hazard ratio for the effect of allocation on time to sputum culture conversion for that study, adjusted for age and sex. We then calculated a weighted average of adjusted hazard ratios for each study and summarized heterogeneity using the I 2 statistic.
Exploration of Variation in Effects
To identify factors modifying the effects of vitamin D supplementation, we did pre- Benjamini-Hochberg procedure for multiple testing correction was applied to the family of P values for interaction to control the false discovery rate (FDR) at 20%.
Risk of Bias Assessment Across Studies
For the primary analysis, the likelihood of publication bias was investigated through the construction of a contour-enhanced funnel plot.
Additional analyses
We did a pre-specified responder analysis in participants assigned to the intervention baseline chest radiograph in addition to the pre-specified adjustments for age, sex and clustering of participants within trials. A pre-specified sensitivity analysis excluding studies deemed at high risk of bias was not conducted, since no included trial fell into this category.
RESULTS
Study Selection and Individual Participant Data Obtained
The study selection process is illustrated in Figure 1 . Our search identified 513 unique studies that were assessed for eligibility, of which 10 studies with a total of 2,223 randomized participants fulfilled eligibility criteria. Individual participant data were sought for all studies, and obtained for 8/10 studies (total 2,096 participants). Individual participant data were not obtained for 2 studies (total of 127 participants): in one case the corresponding author indicated that individual participant data were not available, 8 and in the other, the corresponding author did not respond to an invitation to contribute individual participant data to this meta-analysis. 11 A total of 246 randomized participants in the 8 studies for which individual participant data were obtained were excluded from the meta-analysis on the grounds that they did not have pulmonary tuberculosis confirmed by sputum culture and/or smear. All of the remaining 1,850 participants contributed data to analysis of serious adverse events; 1,163 participants contributed data to analysis of sputum culture conversion, and 1,611 participants contributed data to analysis of sputum smear conversion. Differences in the total number of participants contributing to these analyses represent differences in data availability: serious adverse event data were available for all, but microbiological outcome data were not.
Study and Participant Characteristics
The eight studies for which individual participant data were obtained were conducted in eight countries on three continents ( end-study chest radiograph involvement. 9 Data relating to final treatment outcome were available for 331 participants in two trials 14, 15 (Appendix Table 1 possible by the use of molecular methods in some studies that enabled the rapid detection of mutations associated with drug-resistance. Baseline characteristics of participants were comparable between study arms for the study population as a whole (n=927 allocated to vitamin D vs n=923 allocated to placebo; Appendix Table 2 ) and for the sub-group of participants with multidrug-resistant tuberculosis (n=30 allocated to vitamin D vs n=25 allocated to placebo; Appendix Table 3 ). All studies included sputum smear conversion as an outcome measure; six studies additionally included sputum culture conversion as an outcome measure. 10, 12, 13, [15] [16] [17] Individual participant data integrity checks did not reveal any discrepancies between primary reports vs individual participant data supplied.
Risk of Bias within Studies
Details of the risk of bias assessment are provided in Appendix Table 4 . Four trials were assessed as being at unclear risk of bias due to the relatively high proportion (>20%) of participants who were lost to follow-up. Figure 3 ).
Sub-group analyses, primary outcome
Sub-group analyses were conducted using one-step individual participant data meta- 
Risk of Bias Across Studies
A funnel plot for the outcome of time to sputum culture conversion did not suggest publication bias in relation to this outcome, since randomized controlled trials showed even spread of results on both sides of the overall adjusted hazard ratio (Appendix Figure 1 ).
Responder Analysis
Results of responder analysis are presented in Appendix Table 6 . Among participants randomized to the intervention arm of studies for which end-study 25(OH)D data were available, no difference in time to sputum culture conversion was observed between participants who attained a serum 25(OH)D ≥75 nmol/L vs those who did not.
DISCUSSION
We report results of the first meta-analysis of individual participant data from randomized controlled trials of adjunctive vitamin D in patients with pulmonary tuberculosis. In the study population as a whole, vitamin D supplementation did not influence the primary outcome of time to sputum culture conversion, but it did modestly accelerate sputum smear conversion, which was a secondary outcome. Pre-specified sub-group analysis revealed that vitamin D accelerated sputum culture conversion in participants with multidrug-resistant pulmonary tuberculosis, but not in those whose mycobacterial isolate was sensitive to rifampicin or isoniazid or both. Vitamin D supplementation was safe at the doses administered: no instances of renal stones were seen, and serious adverse events were evenly distributed between participants randomized to vitamin D vs placebo.
Our overall finding of no effect of vitamin D on time to sputum culture conversion is consistent with results from existing systematic reviews and aggregate data metaanalyses, although our findings of accelerated sputum smear conversion are at variance with them. [18] [19] [20] [21] In contrast to the lack of effect overall, the favorable effect of vitamin D on time to culture conversion that we demonstrate in the sub-group of patients with multidrug-resistant tuberculosis is of potential clinical significance. Moreover, it is biologically plausible, since host-directed therapies such as vitamin D are likely to confer greater benefit in scenarios where antimicrobial therapy is less effective. Caution in interpreting results of this sub-group analysis is warranted for several reasons. First, a significant minority (29.1%) of participants with MDR TB did not receive any second-line antimicrobial therapy during their participation in the trials; thus, findings cannot be generalized to patients receiving optimal antimicrobial treatment for MDR TB. Second, the analysis is based on a relatively small number of participantsaccordingly the 95% CI for the adjusted hazard ratio is wide. Third, the potential for a positive result arising by chance as a consequence of several sub-group analyses being conducted cannot be discounted. However, we minimized the potential for type 1 error by pre-specifying a limited number of sub-group analyses, each of which was supported by an independent hypothesis; the P value for interaction for this sub-group analysis 
Strengths and limitations of this study
Our study has several strengths. It is unique in that we had access to individual participant data: this allowed us to conduct sub-group analyses to determine whether effects of vitamin D supplementation varied between individuals. We included data from eight out of ten eligible studies (88% of participants worldwide), none of which were assessed as being at high risk of bias, and restricted analysis to patients who had microbiologically confirmed tuberculosis. Included studies recruited patients from lowand high-incidence settings in three continents, enhancing generalizability of our results.
Our primary outcome of time to sputum culture conversion is accepted as the preferred endpoint for phase II trials of new TB regimens. 27 Our definition captured stable culture conversion only, i.e. if a patient became culture negative but subsequently reverted to culture positive, this was not classified as sputum culture conversion.
Our study also has some limitations. We failed to obtain individual participant data from 2/10 eligible trials. 8, 11 However, neither of these studies investigated our primary outcome of sputum culture conversion, and both were small (n=67 and n=60): their omission therefore has a limited impact on secondary outcomes only. Of note, both trials reported favorable effects of vitamin D on their primary outcome: therefore, if their omission does introduce a bias, that bias would likely be towards the null. Interpretation of the Funnel plot (Appendix Figure 1) is limited by the small number of studies included, but the fact that the smaller randomized controlled trials showed an equal spread of results on both sides of the overall adjusted hazard ratio provides some reassurance that publication bias was not a major issue in our meta-analysis. A further limitation is that end-of-treatment outcomes were not available for meta-analysis: this reflects that fact that almost all trials had relatively short follow-up. However, in the absence of a consistent signal from the phase 2B studies included in this meta-analysis, phase 3 trials of adjunctive vitamin D with end-of-treatment outcomes are not likely to be conducted. Our meta-analysis therefore represents the best evidence in this field that is likely to become available.
Conclusions and policy implications
In conclusion, we show that adjunctive vitamin D does not influence time to sputum culture conversion in drug-sensitive pulmonary tuberculosis, but it may accelerate sputum culture conversion in patients with multidrug-resistant disease. Randomized controlled trials of vitamin D supplementation in patients with multidrug-resistant pulmonary tuberculosis are therefore justified.
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